Plus Therapeutics prices $15M public offering of 39.5M units at $0.38; net ~$13.3M

PLUS THERAPEUTICS, INC.

Offering of 39,473,684 units at $0.38 each, each unit = one share + one warrant.
Gross proceeds $15M; net proceeds ~$13.3M after underwriting discounts and expenses.
Underwriter exercised over-allotment for additional 5,921,052 warrants.
Warrants immediately exercisable at $0.38 per share, expire in 5 years.
Proceeds for working capital; 45-day insiders lock-up and 120-day ban on variable rate transactions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

PLUS THERAPEUTICS, INC. entered into Underwriting Agreement with Lake Street Capital Markets, LLC valued at combined public offering price of $0.38 per share and Warrant (effective 2026-01-13).

Action: entry
Agreement: underwriting
Counterparty: Lake Street Capital Markets, LLC
Value: combined public offering price of $0.38 per share and Warrant
Effective: 2026-01-13

Exact text from the filing

On January 13, 2026, Plus Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as the underwriter (the “Underwriter”), pursuant to which the Company (a) agreed to issue and sell, in an underwritten public offering (the “Offering”), an aggregate of (i) 39,473,684 shares of common stock, par value $ 0.001 per share (the “Common Stock”), of the Company and (ii) warrants to purchase 39,473,684 shares of Common Stock (the “Warrants”), at a combined public offering price of $0.38 per share and Warrant

View on SEC.gov

242 material agreements filed in the last 30 days. Browse all material agreements →

PLUS THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-015346

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.